India, Nov. 3 -- Shilpa CDMO is investing $50 million to expand its peptide manufacturing capabilities as global demand accelerates for GLP-1s and a new generation of more complex peptide therapeutics.

The phased investments will span the next few years and add 10 KL of solid-phase peptide synthesis (SPPS) reactor capacity to the three existing clinical-phase manufacturing lines. A fourth line for commercial manufacturing at Shilpa's Raichur Unit-I campus is already scheduled to open in December 2026, with commercial supply ramping up through 2027.

The CDMO plans to add further 2 KL, 3 KL and 5 KL SPPS reactors, which will establish one of the largest multi-tonne peptide capacities in India.

The new commercial line features 500 L and 1...